A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction

被引:666
作者
Yawn, Barbara P.
Saddier, Patricia
Wollan, Peter C.
Sauver, Jennifer L. St.
Kurland, Marge J.
Sy, Lina S.
机构
[1] Olmsted Med Ctr, Res Dept, Rochester, MN USA
[2] Merck Res Labs, Dept Epidemiol, N Wales, PA USA
[3] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA
关键词
D O I
10.4065/82.11.1341
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: To establish accurate, up-to-date, baseline epidemiological data for herpes zoster (HZ) before the introduction of the recently licensed HZ vaccine. METHODS: Using data from January 1, 1996, to October 15, 2005, we conducted a population-based study of adult residents (222 years) of Olmsted County, MN, to determine (by medical record review) the incidence of HZ and the rate of HZ-related complications. Incidence rates were determined by age and sex and adjusted to the US population. RESULTS: A total of 1669 adult residents with a confirmed diagnosis of HZ were identified between January 1, 1996, and December 31, 2001. Most (92%) of these patients were immunocompetent and 60% were women. When adjusted to the US adult population, the incidence of HZ was 3.6 per 1000 person-years (95% confidence interval, 3.4-3.7), with a temporal increase from 3.2 to 4.1 per 1000 person-years from 1996 to 2001. The incidence of HZ and the rate of HZ-associated complications increased with age, with 68% of cases occurring in those aged 50 years and older. Postherpetic neuralgia occurred in 18% of adult patients with HZ and in 33% of those aged 79 years and older. Overall, 10% of all patients with HZ experienced 1 or more nonpain complications. CONCLUSIONS: Our population-based data suggest that HZ primarily affects immunocompetent adults older than 50 years; 1 in 4 experiences some type of HZ-related complication.
引用
收藏
页码:1341 / 1349
页数:9
相关论文
共 53 条
[41]   Trends in heart failure incidence and survival in a community-based population [J].
Roger, VL ;
Weston, SA ;
Redfield, MA ;
Hellermann-Homan, JP ;
Killian, J ;
Yawn, BP ;
Jacobsen, SJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (03) :344-350
[42]   Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults [J].
Rothberg, Michael B. ;
Virapongse, Anunta ;
Smith, Kenneth J. .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (10) :1280-1288
[43]   Gabapentin for the treatment of postherpetic neuralgia - A randomized controlled trial [J].
Rowbotham, M ;
Harden, N ;
Stacey, B ;
Bernstein, P ;
Magnus-Miller, L .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (21) :1837-1842
[44]   Secular trends in the epidemiology of shingles in Alberta [J].
Russell, M. L. ;
Schopflocher, D. P. ;
Svenson, L. ;
Virani, S. N. .
EPIDEMIOLOGY AND INFECTION, 2007, 135 (06) :908-913
[45]   Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia:: results of a randomised, placebo-controlled clinical trial [J].
Sabatowski, R ;
Gálvez, R ;
Cherry, DA ;
Jacquot, F ;
Vincent, E ;
Maisonobe, P ;
Versavel, M .
PAIN, 2004, 109 (1-2) :26-35
[46]  
Schmader K, 2001, CLIN INFECT DIS, V32, P1481, DOI 10.1086/320169
[47]   Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles [J].
Schuette, MC ;
Hethcote, HW .
BULLETIN OF MATHEMATICAL BIOLOGY, 1999, 61 (06) :1031-1064
[48]   The burden of Herpes Zoster: A prospective population based study [J].
Scott, FT ;
Johnson, RW ;
Leedham-Green, M ;
Davies, E ;
Edmunds, WJ ;
Breuer, J .
VACCINE, 2006, 24 (09) :1308-1314
[49]   Effects of varicella vaccination on herpes zoster incidence [J].
Wagenpfeil, S ;
Neiss, A ;
Wutzler, P .
CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (11) :954-960
[50]   THE PROGNOSIS WITH POSTHERPETIC NEURALGIA [J].
WATSON, CPN ;
WATT, VR ;
CHIPMAN, M ;
BIRKETT, N ;
EVANS, RJ .
PAIN, 1991, 46 (02) :195-199